Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C D Furberg

Showing results (41-50 of 205) with videos related to

Pageof 21
Sort By:
Journal of the American Geriatrics Society|November 1, 1995
Calcium antagonists: antagonists or protagonists of mortality in elderly hypertensives?C D Furberg, B M Psaty
Journal of Thrombosis and Haemostasis : JTH|November 21, 2007
Double-blindness protects scientific validityC D Furberg, E Z Soliman
Circulation|June 1, 1983
Effect of beta-blocker therapy on recurrent nonfatal myocardial infarctionC D Furberg, R L Bell
Circulation|June 1, 1983
What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experienceC D Furberg, R P Byington
European Heart Journal|February 1, 1988
The systolic hypertension in the elderly pilot program: methodological issuesC D Furberg, D M Black
Hypertension (Dallas, Tex. : 1979)|May 1, 1989
The National Heart, Lung, and Blood Institute Workshop on antihypertensive drug treatment. The benefits, costs, and choices. Implications for researchC D Furberg, J A Cutler
Preventive Medicine|July 1, 1985
Drug treatment trials in hypertension: a reviewJ A Cutler, C D Furberg
European Heart Journal|August 27, 1999
Hormone therapy: time for replacement?D M Herrington, C D Furberg
Cardiovascular Clinics|January 1, 1990
Systolic hypertension in the elderly: controlled or uncontrolledJ L Probstfield, C D Furberg
Cardiovascular Drugs and Therapy|September 1, 1996
Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspectiveC D Furberg, B M Psaty
Pageof 21

Showing results (41-50 of 205) with videos related to

Sort By:
Pageof 21
Journal of the American Geriatrics Society|November 1, 1995
Calcium antagonists: antagonists or protagonists of mortality in elderly hypertensives?C D Furberg, B M Psaty
Journal of Thrombosis and Haemostasis : JTH|November 21, 2007
Double-blindness protects scientific validityC D Furberg, E Z Soliman
Circulation|June 1, 1983
Effect of beta-blocker therapy on recurrent nonfatal myocardial infarctionC D Furberg, R L Bell
Circulation|June 1, 1983
What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experienceC D Furberg, R P Byington
European Heart Journal|February 1, 1988
The systolic hypertension in the elderly pilot program: methodological issuesC D Furberg, D M Black
Hypertension (Dallas, Tex. : 1979)|May 1, 1989
The National Heart, Lung, and Blood Institute Workshop on antihypertensive drug treatment. The benefits, costs, and choices. Implications for researchC D Furberg, J A Cutler
Preventive Medicine|July 1, 1985
Drug treatment trials in hypertension: a reviewJ A Cutler, C D Furberg
European Heart Journal|August 27, 1999
Hormone therapy: time for replacement?D M Herrington, C D Furberg
Cardiovascular Clinics|January 1, 1990
Systolic hypertension in the elderly: controlled or uncontrolledJ L Probstfield, C D Furberg
Cardiovascular Drugs and Therapy|September 1, 1996
Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspectiveC D Furberg, B M Psaty
Pageof 21